Cross-linking of SPINK6 by transglutaminases protects from epidermal proteases

Journal of Investigative Dermatology

Volumn 133, Issue 5, 2013, Pages 1170-1177

  Fischer, Jan ^a   Koblyakova, Yulia ^a   Latendorf, Ties ^a   Wu, Zhihong ^a   Meyer Hoffert, Ulf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 1; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 3; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR OF KAZAL TYPE 6; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; EPIDERMIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOREACTIVITY; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STRATUM CORNEUM; WESTERN BLOTTING;

EID: 84876687936     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.482     Document Type: Article

References (36)

1. Aeschlimann D, Paulsson M, Mann K (1992) Identification of Gln726 in nidogen as the amine acceptor in transglutaminase-catalyzed cross-linking of laminin-nidogen complexes. J Biol Chem 267:11316-21
2. Baranger K, Zani ML, Labas V et al. (2011) Secretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafin), a transgluta-minase substrate. PLoS ONE 6:e20976
3. Bayani J, Diamandis EP (2011) Review: the physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). Clin Chem Lab Med 50:211-33
4. Borgono CA, Michael IP, Komatsu N et al. (2007) A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem 282:3640-52
5. Brattsand M, Stefansson K, Hubiche T et al. (2009) SPINK9: a selective, skin-specific kazal-type serine protease inhibitor. J Invest Dermatol 129: 1656-65
6. Briot A, Deraison C, Lacroix M et al. (2009) Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lympho-poietin expression in Netherton syndrome. J Exp Med 206:1135-47
7. Candi E, Tarcsa E, Idler WW et al. (1999) Transglutaminase cross-linking properties of the small proline-rich 1 family of cornified cell envelope proteins. Integration with loricrin. J Biol Chem 274:7226-37
8. Caubet C, Jonca N, Brattsand M et al. (2004) Degradation of corneodesmo-some proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 122:1235-44
9. Chavanas S, Bodemer C, Rochat A et al. (2000) Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 25:141-2
10. Coussons PJ, Price NC, Kelly SM et al. (1992) Factors that govern the specificity of transglutaminase-catalysed modification of proteins and peptides. Biochem J 282:929-30
11. Ekholm IE, Brattsand M, Egelrud T (2000) Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process? J Invest Dermatol 114:56-63
12. Fortugno P, Bresciani A, Paolini C et al. (2011) Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. J Invest Dermatol 131:2223-32
13. Greenberg CS, Birckbichler PJ, Rice RH (1991) Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J 5:3071-7
14. Guyot N, Zani ML, Maurel MC et al. (2005) Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry 44:15610-8
15. Iizuka R, Chiba K, Imajoh-Ohmi S (2003) A novel approach for the detection of proteolytically activated transglutaminase 1 in epidermis using cleavage site-directed antibodies. J Invest Dermatol 121:457-64
16. Ishida-Yamamoto A, Deraison C, Bonnart C et al. (2005) LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J Invest Dermatol 124:360-6
17. Kantyka T, Fischer J, Wu Z et al. (2011) Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6. Peptides 32:1187-92
18. Klucky B, Mueller R, Vogt I et al. (2007) Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res 67:8198-206
19. Komatsu N, Saijoh K, Sidiropoulos M et al. (2005) Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender. J Invest Dermatol 125:1182-9
20. Lose F, Batra J, O'Mara T et al. (2011) Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urol Oncol doi:10.1016/j.urolonc.2011.05.011
21. Lu H, Huang J, Li G et al. (2012) Expression, purification and characterization of recombinant human serine proteinase inhibitor Kazal-type 6 (SPINK6) in Pichia pastoris. Protein Expr Purif 82:144-9
22. McConoughey SJ, Basso M, Niatsetskaya ZV et al. (2010) Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med 2:349-70
23. Meyer-Hoffert U (2009) Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp 57:345-54
24. Meyer-Hoffert U, Wu Z, Kantyka T et al. (2010) Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases. J Biol Chem 285:32174-81
25. Meyer-Hoffert U, Wu Z, Schroder JM (2009) Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. PLoS ONE 4:e4372
26. Nemes Z, Steinert PM (1999) Bricks and mortar of the epidermal barrier. Exp Mol Med 31:5-19
27. Nylander-Lundqvist E, Egelrud T (1997) Formation of active IL-1 beta from pro-IL-1 beta catalyzed by stratum corneum chymotryptic enzyme in vitro. Acta Derm Venereol 77:203-6
28. Schaertl S, Prime M, Wityak J et al. (2010) A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J Biomol Screen 15:478-87
29. Shaw JL, Diamandis EP (2007) Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 53:1423-32
30. Steinert PM, Chung SI, Kim SY (1996) Inactive zymogen and highly active proteolytically processed membrane-bound forms of the transglutaminase 1 enzyme in human epidermal keratinocytes. Biochem Biophys Res Commun 221:101-6
31. Sugimura Y, Hosono M, Kitamura M et al. (2008) Identification of preferred substrate sequences for transglutaminase 1-development of a novel peptide that can efficiently detect cross-linking enzyme activity in the skin. FEBS J 275:5667-77
32. Takahashi M, Tezuka T, Kakegawa H et al. (1994) Linkage between phosphorylated cystatin alpha and filaggrin by epidermal transglutami-nase as a model of cornified envelope and inhibition of cathepsin L activity by cornified envelope and the conjugated cystatin alpha. FEBS Lett 340:173-6
33. Yamane A, Fukui M, Sugimura Y et al. (2010) Identification of a preferred substrate peptide for transglutaminase 3 and detection of in situ activity in skin and hair follicles. FEBS J 277:3564-74
34. Yamasaki K, Di Nardo A, Bardan A et al. (2007) Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13:975-80
35. Yao C, Karabasil MR, Purwanti N et al. (2006) Tissue kallikrein mK13 is a candidate processing enzyme for the precursor of interleukin-1beta in the submandibular gland of mice. J Biol Chem 281:7968-76
36. Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 22:184-204